neostigmine has been researched along with Overweight in 1 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients." | 7.73 | Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. ( Masaki, G; Ogawa, S; Suzuki, T, 2006) |
| "The purpose of this study was to compare neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients." | 3.73 | Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. ( Masaki, G; Ogawa, S; Suzuki, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, T | 1 |
| Masaki, G | 1 |
| Ogawa, S | 1 |
1 other study available for neostigmine and Overweight
| Article | Year |
|---|---|
Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients.
Topics: Adult; Body Mass Index; Body Weight; Cholinesterase Inhibitors; Female; Humans; Middle Aged; Neostig | 2006 |